These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 38206003)

  • 41.
    Pang Y; Zheng H; Tan Y; Song Y; Zhao Y
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242674
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Brown-Elliott BA; Rubio A; Wallace RJ
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126964
    [TBL] [Abstract][Full Text] [Related]  

  • 43.
    Yamatani I; Aono A; Fujiwara K; Asami T; Kamada K; Morishige Y; Igarashi Y; Chikamatsu K; Murase Y; Yamada H; Takaki A; Komiya K; Mitarai S
    Microbiol Spectr; 2024 Jul; 12(7):e0008424. PubMed ID: 38842354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical presentations of nontuberculous mycobacteria as suspected and drug-resistant tuberculosis: Experience from a tertiary care center in Eastern India.
    Das S; Mishra B; Mohapatra PR; Preetam C; Rath S
    Int J Mycobacteriol; 2022; 11(2):167-174. PubMed ID: 35775549
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epidemiology and risk factors associated with NTM pulmonary and extrapulmonary infections in a high tuberculosis endemic Region.
    Wani SR; Wattal C; Raveendran R
    Indian J Med Microbiol; 2020; 38(2):169-175. PubMed ID: 32883930
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibiotic treatment for nontuberculous mycobacterial lung disease.
    Kang YA; Koh WJ
    Expert Rev Respir Med; 2016; 10(5):557-68. PubMed ID: 26967761
    [TBL] [Abstract][Full Text] [Related]  

  • 47.
    Ahmad MN; Garg T; Singh S; Shukla R; Malik P; Krishnamurthy RV; Kaur P; Chopra S; Dasgupta A
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0056422. PubMed ID: 36445129
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preclinical murine models to study lung infection with Mycobacterium abscessus complex.
    Nicola F; Cirillo DM; Lorè NI
    Tuberculosis (Edinb); 2023 Jan; 138():102301. PubMed ID: 36603391
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nontuberculous mycobacteria testing and culture positivity in the United States.
    Marshall JE; Mercaldo RA; Lipner EM; Prevots DR
    BMC Infect Dis; 2024 Mar; 24(1):288. PubMed ID: 38448840
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Cohort Study.
    Wiesel V; Aviram M; Mei-Zahav M; Dotan M; Prais D; Cohen-Cymberknoh M; Gur M; Bar-Yoseph R; Livnat G; Goldbart A; Hazan G; Hazan I; Golan-Tripto I
    J Cyst Fibros; 2024 Jan; 23(1):41-49. PubMed ID: 37173154
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epidemiology of Nontuberculous Mycobacteria in Tuberculosis suspects, Southwest of China, 2017-2022.
    Wang DM; Liu H; Zheng YL; Xu YH; Liao Y
    Front Cell Infect Microbiol; 2023; 13():1282902. PubMed ID: 38029240
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria.
    van Ingen J; Boeree MJ; van Soolingen D; Mouton JW
    Drug Resist Updat; 2012 Jun; 15(3):149-61. PubMed ID: 22525524
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Extremely Low Hit Rate in a Diverse Chemical Drug Screen Targeting Mycobacterium abscessus.
    Malin JJ; Winter S; van Gumpel E; Plum G; Rybniker J
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427298
    [No Abstract]   [Full Text] [Related]  

  • 54. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus.
    Johansen MD; Herrmann JL; Kremer L
    Nat Rev Microbiol; 2020 Jul; 18(7):392-407. PubMed ID: 32086501
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antimicrobial susceptibility of nontuberculous mycobacteria from eye infections.
    Brown-Elliott BA; Mann LB; Hail D; Whitney C; Wallace RJ
    Cornea; 2012 Aug; 31(8):900-6. PubMed ID: 22362004
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?
    Ruth MM; Koeken VACM; Pennings LJ; Svensson EM; Wertheim HFL; Hoefsloot W; van Ingen J
    J Antimicrob Chemother; 2020 Mar; 75(3):609-617. PubMed ID: 31886864
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Repurposing disulfiram to target infections caused by non-tuberculous mycobacteria.
    Das S; Garg T; Chopra S; Dasgupta A
    J Antimicrob Chemother; 2019 May; 74(5):1317-1322. PubMed ID: 30753528
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution.
    Fröberg G; Maurer FP; Chryssanthou E; Fernström L; Benmansour H; Boarbi S; Mengshoel AT; Keller PM; Viveiros M; Machado D; Fitzgibbon MM; Mok S; Werngren J; Cirillo DM; Alcaide F; Hyyryläinen HL; Aubry A; Andres S; Nadarajan D; Svensson E; Turnidge J; Giske CG; Kahlmeter G; Cambau E; van Ingen J; Schön T;
    Clin Microbiol Infect; 2023 Jun; 29(6):758-764. PubMed ID: 36813087
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clomiphene Citrate Shows Effective and Sustained Antimicrobial Activity against
    Lee DG; Hwang YH; Park EJ; Kim JH; Ryoo SW
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681686
    [No Abstract]   [Full Text] [Related]  

  • 60. Implication of species change of Nontuberculous Mycobacteria during or after treatment.
    Lee JS; Lee JH; Yoon SH; Kim TS; Seong MW; Han SK; Yim JJ
    BMC Pulm Med; 2017 Dec; 17(1):213. PubMed ID: 29262802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.